Validation of the performance of a point of care molecular test for leprosy:

- 2 from a simplified DNA extraction protocol to a portable qPCR
- Amanda Bertão-Santos¹, Larisse da Silva Dias², Marcelo Ribeiro-Alves³, 3
- Roberta Olmo Pinheiro², Milton Ozório Moraes^{2,†}, Fernanda Saloum de Neves 4
- Manta^{2*}, Alexandre Dias Tavares Costa^{1*} 5
- ¹ Laboratório de Ciências e Tecnologias Aplicadas à Saúde (LaCTAS), Instituto 6
- 7 Carlos Chagas, Fundação Oswaldo Cruz (FIOCRUZ), Curitiba, Brazil
- ² Laboratório de Hanseníase, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz 8
- (FIOCRUZ), Rio de Janeiro, Brazil 9
- 10 ³ Laboratório de Pesquisa Clínica em DST e AIDS, Instituto Nacional de
- Infectologia Evandro Chagas, Fundação Oswaldo Cruz (FIOCRUZ), Rio de 11
- Janeiro, Brazil 12

1

- * FSNM and ADTC contributed equally to this work 13
- Corresponding authors: alexandre.costa@fiocruz.br; adtcosta@gmail.com; 14
- femanta@yahoo.com.br 15
- † In memoriam 16

25

- 17 **Short title:** A fully portable molecular test for Mycobacterium leprae detection
- 18 Funding: This study was supported by grants from Carlos Chagas Filho
- Research Support Foundation of the State of Rio de Janeiro (Faperi, E-19
- 26/203.913/2022) Carlos Chagas Institute Research Stimulus Program (ICC 008 20
- 21 FIO 21 – SUB 22) and by the National Fund for Health/Brazilian Ministry of Health
- (TED 69/2021). LSD is a CNPq fellowship holder, FSNM is a Faperj fellowship 22
- holder, and ADTC is a CNPg productivity fellow (level 2). 23
- **Disclosure:** All authors declare no conflict of interest. 24

Abstract

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

The study aimed to optimize gPCR reactions using oligonucleotides from the first Brazilian molecular diagnostic kit for leprosy on a portable platform (Q3-Plus). In addition, we sought to develop a simplified protocol for DNA extraction that met point-of-care criteria. During optimization on the Q3-Plus, optical parameters, thresholds, and cutoffs for the 16S rRNA and RLEP targets of M. leprae were established using synthetic DNA, purified DNA from M. leprae, and precharacterized clinical samples. In the simplified extraction step, different lysis solutions were evaluated using chaotropic agents, and purification was carried out by depositing the lysed material on FTA cards. The complete protocol (simplified extraction + qPCR on the portable platform) was evaluated with precharacterized clinical skin biopsy samples and compared with standard equipment (QuantStudio-5). LOD_{95%} for the optimized reactions was 113.31 genome-equivalents/µL for 16S rRNA and 17.70 genome-equivalents/µL for RLEP. Among the lysis solutions, the best-performing was composed of urea (2 M), which provided good dissolution of the skin fragment and a lower Ct value, indicating higher concentrations of DNA. The complete technological solution showed a sensitivity of 52% in reactions. Our results highlight the need for additional optimization to deal with paucibacillary samples, but also demonstrate the applicability of the portable platform in the detection of M. leprae in low infrastructure settings.

Keywords: diagnostic test; leprosy; point-of-care; DNA extraction; portable gPCR

Introduction

Leprosy is a chronic and progressive infectious disease with worldwide distribution caused by *Mycobacterium leprae* or *M. lepromatosis* (HAN et al., 2008). It presents tropism for peripheral nerves and skin, although other organs might also be affected. Progression of the disease might cause deformities and different degrees of physical disability (FI). Given its signs and symptoms, leprosy can be manifested in a broad spectrum of clinical forms, some of which often lead to misdiagnosis with other dermatological, osteoarticular, or neurological conditions, and even other diseases (NEVES et al., 2023; DHARMAWAN et al., 2022).

Early diagnosis is essential for proper treatment and control of the disease's clinical progression and community transmission (STEINMANN et al., 2017). Due to its inability to grow *in vitro*, direct diagnostic techniques such as culture and isolation are not feasible (MACIEIRA, 2000). Diagnosis is usually late or non-existent because it is mainly based on the patient's clinical and epidemiological information, guided by anamnesis and physical examination, which demands physician's expertise (WHO, 2022; HENRY et al., 2016). In the absence of a gold standard diagnostic test, complementary tests are often employed, such as histopathology and bacilloscopy of the slit-skin smear. These tests, however, exhibit variations in sensitivity accordingly the clinical form of the disease and rely on experience for contextualization and interpretation (NEVES et al., 2023; WHO, 2022; HENRY et al., 2016).

Molecular tests, particularly real-time polymerase chain reaction (qPCR), are sensitive and specific, contributing to the early identification of various pathologies (MADAMET et al., 2022; RAMPAZZO et al., 2022; YU et al., 2021).

Although molecular detection tests are available, the diagnosis of leprosy continues to rely primarily on clinical diagnosis (WHO, 2022). This is due to the variations in clinical presentations, especially in multibacillary and paucibacillary cases, as the analytical sensitivity of tests varies according to the bacillary load of the infection (BARBIERI et al., 2019).

Recently, Brazilian health authorities (ANVISA) granted registration for the first national qPCR NAT Hans kit (IBMP, Brazil), developed by the Oswaldo Cruz Foundation (Fiocruz/RJ) (MANTA et al., 2022). This kit specifically targets the genetic markers 16S rRNA and RLEP M. leprae, demonstrating sensitivity and specificity of 91% and 100%, respectively. Additionally, it utilizes human 18S rRNA as an internal control, ensuring proper DNA extraction. The incorporation of this molecular test into the routine of healthcare professionals engaged in active case finding for leprosy can overcome the intrinsic limitations of direct diagnostic methods such as bacilloscopy, histopathology, and indirect serology tests, thereby expanding the detection capacity, especially for the paucibacillary (PB) clinical form (BARBIERI et al., 2019).

Tools that assist in population screening play a crucial role in active case finding and early diagnosis of leprosy. Screening tests exhibit higher sensitivity, meaning they can more accurately identify positive cases for the disease of interest. A positive result in a screening test should guide the patient toward further assessments that allow for an accurate diagnostic investigation, as is done in the case of leprosy (WHO, 2020). However, the implementation of leprosy molecular detection tests in the field faces limitations. The requirement for thermolabile reagents and robust equipment hinders access to diagnosis in remote and low-infrastructure regions. Furthermore, the method requires prior

DNA extraction, demanding investments in costly commercial kits and time-consuming to obtain the sample (MANTA et al., 2020; ALI et al., 2017; WANG et al., 2016). Regarding nucleic acid testing (NAT) based diagnosis, the primary challenges are related to the pre-analytical phase, including specimen collection and biological material extraction. The need for sensitive instruments, such as centrifuges, and high-cost reagents, as well as the proper disposal of the chemical residues generated in these steps, represents the primary limitations for their applicability in resource-limited settings (ALI et al., 2017; DINEVA et al., 2007).

The aim of the study was optimizing qPCR reactions using the NAT Hans kit (IBMP, Brazil) on the portable Q3-Plus instrument, while concurrently developing a simplified DNA extraction protocol for skin samples, aiming the detection of *M. leprae* DNA. The resulting prototype enables the implementation of a leprosy screening test in remote areas, facilitating the active search of positive cases and monitoring by health authorities responsible for underserved populations.

Materials and Methods

Ethics Statement

The present research project was approved by the Ethics Committee of the Oswaldo Cruz Institute (CAAE: 52565521.2.0000.5248, number: 5.131.588 approved on November 26, 2021). Suspected leprosy patients attending the Souza Araújo Out-Patient Unit (ASA), a leprosy reference center from Brazilian Ministry of Health at Oswaldo Cruz Institute – Fiocruz – RJ – Brazil, provided written consent to participate in the project. In the case of minors, formal written

consent was obtained from the patient's guardian. The selection of samples was carried out according to the occurrence of cases attended at the clinic.

Synthetic DNA

Synthetic double-stranded DNA (gBlock, IDT, USA) containing the sequences of genomic markers for *M. leprae* (*16S rRNA* and RLEP) and the human genomic marker (*18S rRNA*) was used for the optimization of qPCR reactions on the portable equipment (Q3-Plus). Paired evaluations were also performed on the standard equipment (Quantstudio 5 – QS-5). The lyophilized synthetic DNA was constituted at 10 fg/μL (equivalent to 10⁴ copies/μL). To obtain the sample at 10⁵ copies/μL, the gBlock was amplified by qPCR, and its product was purified using the QIAquick PCR Purification Kit (Qiagen, Germany). The concentration was determined by interpolating Cycle threshold (Ct) values on the standard curve. When necessary, samples were diluted in Tris-EDTA (TE) buffer (pH 8.0) for standard curve analyses.

M. leprae cells

M. leprae cells (Thai-53, at 10⁶ cells/mL) obtained from nude mice footpads were kindly provided by Dr. Patricia Sammarco Rosa from Lauro de Souza Lima Institute (Bauru, São Paulo, Brazil).. The cells were diluted at 1:10 in Tris-EDTA (TE) buffer (pH 8.0) for the construction of the standard curve.

Determination of optical parameters, threshold, and cutoff in the optimization of the portable equipment: Q3-Plus

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

For the determination of optical parameters corresponding to readings through the FAM, VIC, and ROX channels on the Q3-Plus equipment, different values of exposure time, gain, and light intensity were evaluated (TABLE 1). The alterations aimed to improve the sensitivity of the reactions and achieve a good fluorescence amplitude. To achieve this, various concentrations $(10^4 - 10^0)$ copies/µL) of synthetic DNA were evaluated using gPCR on the portable platform. and based on reaction efficiency and amplification curve characteristics, the parameters were assessed.

TABLE 1 - Optical parameters, including exposure time, gain and LED power. were assessed for reading analyses using the Q3-Plus equipment. *FAM – Probe to target 16S rRNA of M. leprae; VIC - probe to target RLEP of M. leprae; ROX -Probe to target 18S rRNA of mammals

FAM			,	VIC		ROX			
Exposure Time (s)	Gain	LED Power	Exposure Time (s)	Gain	LED Power	Exposure Time (s)	Gain	LED Power	
1	14	5	1/2	11	5	1	15	7	
1	14	7	1/2	15	8	-	-	-	
1	14	8	1/2	15	9	-	-	-	
1	15	7	1/2	15	10	-	-	-	
1	15	10	1	14	5	-	-	-	
-	-	-	1	14	9	-	-	-	

It is made available under a	CC-BY	Y 4.0 International license	
------------------------------	-------	-----------------------------	--

-	-	-	1	15	8	-	-	-
-	-	-	2	13	10	-	-	-
-	-	-	2	14	7	-	-	-
-	-	-	2	14	9	-	-	-
-	-	-	2	15	7	-	-	-
-	-	-	2	15	10	-	-	-
-	-	-	2	16	10	-	-	-

The baseline was automatically defined by the instrument's software (Q3-Plus V2 Suite, version 4.0, ST Microelectronics). The threshold for each target was manually set by the operator through observation of fluorescence amplitude patterns and images captured by the software during reaction cycles with different concentrations of synthetic DNA, purified *M. leprae* DNA, pre-characterized clinical samples, as well as negative controls.

The establishment of the Ct value for the cutoff was conducted in the final stage of the study. For this purpose, two groups of pre-characterized clinical samples were analyzed: (i) The "standard" group consisted of skin biopsy samples extracted using a standardized commercial kit; (ii) The second group consisted of samples extracted using the protocol developed in the present study.

A Bland-Altman analysis was performed (ALTMAN & BLAND, 1983). The mean variations on Ct values to different equipment for the targets were added to the values of cutoff already established in the NAT Hans kit (IBMP, Brazil).

Standard curve and analytical sensitivity on Q3-Plus and Quantstudio-5 equipment

The efficiency and determination of the detection limit for the qPCR reactions on the portable Q3-Plus instrument were obtained through a standard curve with logarithmic scale dilutions using synthetic DNA or purified *M. leprae* DNA (referred to as equivalent- genomes). The efficiency calculation for the reactions was done by substituting the slope value of the linear regression line into the efficiency formula (E=(10(-1/slope)-1).*100), following the MIQE Guidelines (BUSTIN *et al.*, 2009).

The number of equivalent genome copies was estimated by interpolating Ct values obtained from the analysis of purified *M. leprae* DNA using the equation established after linear regression of the curve performed with synthetic DNA, considering known concentrations and the number of copies (10 fg/µL equivalent to 10⁴ copies/µL of synthetic DNA). For the analysis of the analytical sensitivity of the reaction, seven dilution points were considered, with a higher number of replicates (nine or ten) for the lower concentrations (BURD, 2010).

As a reference, identical analyses were performed using the standard Quantstudio-5 (QS-5) equipment.

Reproducibility and Repeatability of qPCR reactions using synthetic DNA on the portable equipment.

The reproducibility of the reaction was carried out by the independent operators over three consecutive days for concentrations ranging from 10⁴ to 10⁰ copies/µL. Subsequently, for three consecutive days, the same operators performed three reactions with lower concentrations ranging from 10¹ to 10⁰

copies/µL. This division was due to the inherent limitation of the number of reactions that can be analyzed per chip (six wells). For each replicate, a new dilution was performed using synthetic DNA as the sample and Tris-EDTA buffer (pH 8.0) as the diluent (BURD, 2010).

Clinical Samples

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

Germany) were used.

The clinical samples obtained in the present study were collected based on the occurrence of attendance at the Souza Araújo Clinic from the Oswaldo Cruz Foundation (Rio de Janeiro, Brazil). Skin biopsy collections were performed using a 3 mm surgical punch and stored in 70% ethanol until sample processing. Following clinical assessment, the samples were characterized according to established protocols, including clinical evaluation, histopathology, bacilloscopy, and singleplex qPCR (16S rRNA). Cases were classified as multibacillary (MB), paucibacillary (PB), or other dermatoses (OD) following WHO guidelines (WHO, 2018). This study utilized 115 clinical skin biopsy samples, comprising 41 MB, 25 PB, and 49 OD (Supplemental Table S1). Of these, DNA was extracted from 62 skin biopsy samples (27 MB, 16 PB, and 19 OD) using commercial DNAeasy Blood and Tissue (Qiagen, Germany) and, 53 skin biopsy samples from leprosy patients and suspects (14 MB, 9 PB, and 30 OD) were extracted using both commercial DNAeasy Blood and Tissue (Qiagen, Germany) and the simplified DNA extraction protocol. For the optimization of gPCR reactions on the portable equipment (Q3-Plus), exclusively samples extracted by the commercial protocol (Qiagen,

Standard methods used as guides for the methods developed

As a guide method for the protocols developed in the present study, clinical samples were also subjected to DNA extraction using a commercial kit. qPCR analyses using the NAT Hans kit were performed on a standard qPCR instrument (QuantStudio-5).

Commercial DNA Extraction

DNA extraction from skin biopsy samples (3 mm) stored in 70% alcohol was performed using DNAeasy Blood and Tissue® extraction kit (Qiagen, Germany) according to the manufacturer protocol. DNA concentration was estimated using NanoDrop® (Thermo-Fisher Scientific, Waltham, MA, USA) and immediately stored at -20 °C.

Experimental conditions for multiplex qPCR (NAT Hans) in standard equipment: QuantStudio 5

Detection of the two *M. leprae* targets (*16S rRNA* and RLEP) and the human internal control (*18S rRNA*) was performed as previously described by MANTA et al. (2022). Reactions were performed in a standard benchtop instrument (QuantStudio-5, Applied Biosystems, USA). Reactions were performed using the NAT Hans kit and were analyzed as manufacturer's instructions. Reactions' final volume was 25 μ L, containing 5 μ L of DNA. Cycling conditions used in QS-5 were 95 °C for 10 minutes, 45 cycles of 95 °C for 15 seconds, and 60 °C for 1 minute.

Development of DNA extraction protocol and evaluation of the qPCR reactions in Q3-Plus

Evaluation of lysis solutions utilizing the porcine skin model

Due to limitations regarding the availability of clinical samples from leprosy and suspected leprosy patients, porcine skin was used as a comparative model for the evaluation of six different solutions of lysis to DNA extraction protocols (TABLE 2) (HWANG et al., 2021; SUMMERFIELD et al., 2015). The evaluations were established in two ways: (i) visual observation regarding the dissolution/reduction of the skin fragment and changes in solution turbidity, and (ii) through qPCR for amplification of the mammalian *18S rRNA* gene (MANTA et al., 2020), as an analysis of the efficiency of each protocol. For the extraction of negative control, a pig skin fragment incubated with nuclease-free water was used, which underwent the same processing protocol as the other samples.

TABLE 2 – Lysis solutions were assessed in protocols aimed at developing a simplified extraction method. Shown are the protocols and reagents with their respective concentrations and volumes necessary for the preparation of lysis solutions evaluated in DNA extraction from 6 mm skin biopsies.

Solution	Skin Biopsy	PBS	Guanidine	PK	Urea	NH₄OH	Tx100	SDS	Nuclease -free water	Total	[F	inal]	
[Stock]		5.8 mM	6 M	20 mg/mL	8 M	71 mM	10%	10%			Guanidine	Urea	NH₄OH
1	6 mm	200 µL	200 μL	8 µL	160 µL	-	32 µL	-		600 µL	2	2	-
2	6 mm	366 µL	-	14.6 µL	146 µL	-	_	-	73.4 µL	600 µL	-	2	-
3	6 mm	-	286 μL	29 µL	286 µL	-	-	-		600 µL	3	4	-
4	6 mm	-	428 µL	34 µL	-	-	138 µL	-		600 µL	4	-	-
5	6 mm	-	540 µL	60 µL	-	-	-	-		600 µL	5	-	-
6	6 mm	-	-	-	-	540 µL	-	60 µL		600 µL	-	-	0.06

Fragments of porcine skin, approximately 3 mm, were placed in microtubes containing each of the evaluated lysis solutions (TABLE 2). Subsequently, each sample was gently macerated using a sterile microtubes pestle and incubated at 56 °C for 30 minutes in a heating block, with additional maceration and vortex agitation every ten minutes. Subsequently, 200 μ L of the supernatant was deposited onto FTA Elute Micro Card TM (Flinders Technology Associates – FTA, GE Whatman, Maidstone, Kent, United Kingdom) cards and stored at room temperature (21 – 23 °C) until completely dry to proceed with the purification and elution step.

Clinical sample (biopsy) preparation and application onto FTA Micro Elute® card

Upon establishing the optimal skin biopsy DNA extraction protocol, a subsequent phase of clinical sample assessment was undertaken. To refine and appraise the streamlined protocol, the biopsy specimen was introduced into a 1.5 mL microtube, containing 146 μL of denaturing solution (8 M urea solution), 14.6 μL of proteinase K (20 mg/μL) (Roche, Germany), 366 μL of phosphate-buffered saline (PBS) (5.8 mM), and 73.4 μL of nuclease-free water (SOLUTION 2- TABLE 2). Following this, employing a sterile microtube pestle, the sample was meticulously macerated and then subjected to a 30-minute incubation at 56 °C within a thermal block. Additional rounds of maceration and vortex agitation were performed at ten-minute intervals. Subsequently, 200 μL of the resulting supernatant was meticulously deposited onto an FTA Elute Micro CardTM, where it was diligently preserved at ambient temperature (21 – 23 °C) until complete desiccation.

DNA elution protocols

Ten elution protocols were evaluated using clinical skin biopsy samples with lysis solution (urea solution) stored on FTA cards (FIGURE 1). The first parameter assessed was the size of the FTA fragment to be punched out: both 3 mm and 6 mm fragments were evaluated. Subsequently, direct elution by TE buffer (pH 8.0) and the implementation of a washing step were examined. The commercial FTA wash buffer (200 μL, Qiagen, Germany) and nuclease-free water (500 μL) were tested for washing. Finally, the addition of 50 μL and 100 μL of elution buffer TE (pH 8.0), followed by incubation at 95 °C for 5 min, 10 min and 15 min were evaluated. The eluate containing the extracted DNA obtained with each protocol was subjected to a qPCR reaction to detect the *16S rRNA* and RLEP targets of *M. leprae* and the human *18S rRNA* internal control using the NAT Hans kit (IBMP, Brazil).

Fig 1. Flowchart displaying the elution protocols from FTA cards evaluated in the extraction of *Mycobacterium leprae* DNA from skin biopsy samples

Experimental conditions for qPCR multiplex in a portable instrument (Q3-Plus)

The reactions for detection of *M. leprae* targets (*16S rRNA* and RLEP) and the human internal control (*18S rRNA*) were performed on the Q3-Plus instrument used the GoTaq Probe qPCR Master Mix (2X) (Promega, USA) and the same oligonucleotides described by Manta et al. (2022), which are used in the NAT Hans kit. For the *16S rRNA* target at concentrations of 0.75 µM for the forward and reverse oligonucleotides, and 0.3 µM for the probe; for the RLEP target, 0.4

 μ M for the forward and reverse oligonucleotides, and 0.2 μ M for the probe; and the *18S rRNA* target, 0.2 μ M for both forward and reverse, and 0.1 μ M for the probe. Despite this, due to the specificities of the portable instrument, it was necessary to replace the Cy5 fluorophore with ROX, which is the probe used for the detection of the *18S rRNA* gene. On the portable platform, the reactions were standardized to a final volume of 5 μ M, containing 2 μ M of DNA.

Optical parameters for the FAM channel were exposure time 1 second, gain 14, and light power 8; for the VIC channel, parameters were exposure time 1 second, gain 14, and light power 9; finally, for the ROX channel, optimized parameters were exposure time 1 second, gain 15, and light power 7. The baseline was defined automatically by the instrument software (Q3-Plus V2 Suite, version 4.0, ST Microelectronics), and the established threshold was 36 arbitrary units (a.u.) for the target 16S rRNA, 150 u.a. for RLEP and 21 u.a. for 18S rRNA defined according to fluorescence amplitude patterns observed at different concentrations of gBlock, from *M. leprae* genome-equivalents, negative controls, and pre-characterized clinical samples.

Cycling conditions were 95 °C for 2 minutes, 45 cycles of 95 °C for 15 seconds, and 64 °C for 1 minute. The total reaction time on the portable equipment was approximately 1 hour and 40 minutes.

Statistical analysis

Diagnostic parameters such as reaction's efficiency, sensitivity, specificity, reproducibility, and repeatability were evaluated for the best experimental protocol using qPCR carried out on both instruments (QuantStudio-5 and Q3-Plus). The detection limit with 95% confidence interval ($LOD_{95\%}$) was calculated

using the Probit model using RStudio version 4.1.0 software (downloaded from http://www.Rproject.org/). The evaluation of the agreement between the different instruments was carried out using the Bland-Altman method (ALTMAN & BLAND. 1983).

This study follows the STARD guidelines for reporting diagnostic accuracy studies (COHEN et al., 2016). The minimum information for publication of quantitative real-time PCR experiments (MiQE) (BUSTIN et al., 2009), as well as the STARD checklist, are presented as Supplemental Tables S2 and S3.

Results

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

Optimization of reactions for detection of *M. leprae* DNA in the portable

instrument

Optical parameters and efficiency of reactions

Different values of optical parameters were evaluated in the optimization of reactions in the Q3-Plus instrument (TABLE 1). The alterations sought to increase the sensitivity and efficiency in the reactions by the instrument, through the greater amplitude of fluorescence. For FAM exposure time 1, gain 14, and light power 8 was set, while for the channel VIC the parameters were exposure time 1, gain 14, and light power 9, and for the channel ROX the optimized parameters were exposure time 1, gain 15, and light intensity 7.

The fluorescence threshold for each target was set at 36 a.u. for the 16S rRNA target (FAM), 150 a.u. for the RLEP target (VIC) of M. leprae, and 21 a.u. for the 18S rRNA target (ROX), the human internal control.

The efficiency was calculated based on a dilution curve $(10^5 - 10^0)$ copies/µL) of synthetic DNA (gblock) results. For Q3-Plus equipment the

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

efficiency was 109% for the 16S rRNA gene and 108% for the RLEP target. The standard QS-5 equipment showed 102% efficiency for 16S rRNA and 94% for RLEP (FIGURE 2). Fig 2. Standard curve of qPCR reactions analyzed by QuantStudio and Q3-Plus equipment for the detection of Mycobacterium leprae 16S rRNA and **RLEP targets from synthetic DNA** (A) Reactions on QuantStudio 5; (B) Reactions on portable platform Q3-Plus. Linear regressions were obtained from no less than 4 independent experiments The same analyzes were performed from reactions with DNA samples of the genome- equivalent to 106 cells/µL of M. leprae. The efficiency of 131% for the reactions of the 16S rRNA target and 105% for the RLEP target were observed in the Q3-Plus equipment, and an efficiency was 101% for 16S rRNA and 100% for RLEP in the QS-5 equipment (FIGURE 3). Fig 3. Standard curve of qPCR reactions analyzed by QuantStudio and Q3-Plus equipment for the detection of Mycobacterium leprae 16S rRNA and RLEP targets using purified DNA from M. leprae (A) Reactions on QuantStudio 5; (B) Reactions on portable platform Q3-Plus. Linear regressions were obtained from no less than 4 independent experiments.

Analytical sensitivity

The limit of detection (LOD_{95%}) on the Q3-Plus equipment using synthetic DNA was 13.86 copies/μL for the *16S rRNA* and RLEP targets. On the QS-5 equipment, the respective values were found to be 12.45 copies/μL for *16S rRNA* and 20.44 copies/μL for RLEP. When using purified *M. leprae* DNA, the LOD_{95%} on the Q3-Plus instrument was 113.31 genome-equivalents/μL for the *16S rRNA* gene and 17.70 genome-equivalents/μL for the RLEP (Fig 4). On the standard equipment (QS-5), the values were 205.26 genome-equivalents/μL for *16S rRNA*, and 15.34 genome-equivalents/μL for the RLEP.

Fig 4. Analytical sensitivity of qPCR reactions for the targets 16S rRNA and RLEP of Mycobacterium leprae performed on the portable Q3-Plus equipment. (A) LOD95% 16S rRNA; (B) LOD95% RLEP.

Reproducibility and repeatability in the portable equipment

Results obtained in the intra- and inter-operator replicate series are shown in TABLE 2 and show the coefficients of variation observed in the intra-operator reactions at the lowest concentrations (10¹ – 10⁰ copies/µL). Although these values are greater than 5%, they are lower than 10%, thus being non-significant for both the *16S rRNA* and RLEP targets. In the inter-operator analyses the coefficient of variation values between concentrations was between 0.05 and 3.09% for the *16S rRNA* gene. For the RLEP target, values ranged from 0.55 to 3.10%. The analysis of variance (ANOVA) performed for the results obtained by the different operators, assuming a confidence interval of 95%, corroborated the

- previous analyses, showing no significant inter-operator difference (p-value = 421
- 0.994 for 16S rRNA, and p-value = 0.992 for RLEP) (TABLE 3). 422

TABLE 3 – Repeatability and reproducibility analyses, including the respective coefficients of variation, were determined in qPCR reactions targeting *Mycobacterium leprae 16S rRNA* and RLEP on the Q3-Plus equipment.

Target	Synthetic		Repeatability								Reproducibility						
rarget	DNA		Opera	ator 1			Operator 2				Operator 3			Interoperator			
	Copies/µL	mean	desv	desv pad	%rRSD	mean	desv	desv pad	%rRSD	mean	desv	desv pad	%rRSD	mean	desv	desv pad	%rRSD
Mean Ct	1,00E+04	22.83	0.25	0.32	1.41	22.78	0.26	0.35	1.55	22.66	0.10	0.15	0.68	22.76	0.06	0.09	0.39
16S	1,00E+03	26.61	0.11	0.15	0.55	26.60	0.12	0.16	0.61	26.62	0.07	0.09	0.35	26.61	0.01	0.01	0.05
rRNA	1,00E+02	30.05	0.30	0.39	1.31	29.75	0.14	0.19	0.65	30.16	0.30	0.43	1.43	29.99	0.16	0.21	0.71
	1,00E+01	33.71	0.91	1.18	3.49	34.07	1.34	1.97	5.80	34.40	0.60	0.60	1.73	34.06	0.23	0.34	1.01
	1,00E+00	34.65	0.51	0.74	2.13	36.47	1.14	1.44	3.96	36.67	2.39	3.39	9.23	35.93	0.85	1.11	3.09
	1,00E+04	28.77	0.23	0.32	1.13	29.19	0.96	1.27	4.34	28.56	0.51	0.68	2.38	28.84	0.23	0.32	1.11
Maan Ct	1,00E+03	31.84	0.21	0.28	0.87	32.36	0.61	0.80	2.46	32.03	0.18	0.24	0.76	32.07	0.19	0.26	0.82
Mean Ct RLEP	1,00E+02	35.20	0.26	0.34	0.97	34.90	0.25	0.35	1.00	35.30	0.51	0.67	1.91	35.13	0.15	0.21	0.59
KLEP	1,00E+01	38.75	0.92	1.07	2.75	38.72	1.24	1.61	4.17	39.10	0.17	0.26	0.66	38.86	0.16	0.21	0.55
	1,00E+00	40.44	1.46	2.06	5.10	38.11	*	*		38.70	0.94	1.33	3.44	39.08	0.91	1.21	3.10

Evaluation of the portable qPCR using DNA from skin biopsies

A difference in the Ct value was observed for the same 95 samples extracted by commercial kit when analyzed on different instruments. The mean Ct difference for the same samples between the instruments resulted in an increase of 1.40 cycles for the Q3-Plus instrument to 16S rRNA target and an increase of 5.15 cycles for the RLEP target when compared to that obtained in the standard instrument analysis (Supplemental Figure S1 and S2). In the internal control (18S rRNA) there was a mean increase of 1.42 cycles on Q3-Plus analysis (Supplemental Figure S3). Cycle values above these means were mainly observed in samples classified as PB, where a lower concentration of the target DNA is expected.

To determine the cutoff to reactions on Q3-Plus, the mean difference observed between the instruments for the different targets was added to the values established for the NAT Hans kit. In this protocol, the cutoff values for targets are Ct 35.5 for 16S rRNA; and Ct 34.5 for RLEP. Therefore, for the reactions analyzed in Q3-Plus the Ct cutoffs established for the 16S rRNA target was 36.9, and for the RLEP target it was 39.6. Consequently, for samples that exhibited amplification for both targets, with values below 36.9 and 39.6 for the 16S rRNA and RLEP, respectively, they were classified as positive on the Q3-Plus equipment. For those samples that displayed Ct values above the cutoff point or absence of amplification, a classification of negative assigned. Moreover, samples that exhibited amplification in only one of the targets (16S rRNA or RLEP) were classified as indeterminate. In these cases, a retest of the sample and patient follow-up is recommended. In this study, of all 95 samples analyzed,

43% (41/95) were considered qPCR positive for the presence *M. leprae* DNA, 43% (41/95) negative, and 14% (13/95) indeterminate.

On the standard equipment (QS-5), the same samples evaluated using the NAT Hans kit were classified as positive, negative, or indeterminate according to the recommendation cutoff of the commercial kit protocol. Following the analysis, 47% (45/95) of the samples were determined as positive, while 40% (38/95) were negative for the agent. The remaining 13% (12/95) of the samples were classified as indeterminate.

The NAT Hans reactions on Q3-Plus equipment demonstrated a sensitivity of 73% and specificity of 85%. However, out of the 95 samples analyzed, 14% (13/95) yielded indeterminate results. The same reactions conducted on the standard equipment (QS-5) showed a sensitivity of 77%, specificity of 77%, and 13% (12/95) of samples with indeterminate results (TABLE 4). The positive predictive values for the Q3-Plus equipment were 88%, and for the QS-5, it was 82%. The negative predictive values were 68% and 71% for Q3-Plus and QS-5 equipment, respectively. Regarding the accuracy of the tests, it was 78% for Q3 equipment and 77% QS-5.

TABLE 4 - Comparison of molecular diagnostic parameters in clinical biopsies extracted by commercial protocol and evaluated in ABI7500, QuantStudio-5 and Q3-Plus platforms

Commercial extraction					
Quantstudio 5	Q3-Plus				
77%	73%				
77%	85%				
77%	78%				
82%	88%				
71%	68%				
	Quantstudio 5 77% 77% 77% 82%				

Analysis of extractions protocols

Evaluation of Lysis Solutions for Porcine Skin Models

Several different lysis solutions devised to simplify the DNA extraction process from skin samples were evaluated visually and by qPCR using porcine skin as model tissue (HWANG et al., 2021; SUMMERFIELD et al., 2015). TABLE 5 summarizes all six protocols that were evaluated and the corresponding mean Ct for qPCR detection of the mammalian *18S rRNA* gene. A mixture consisting of urea (2 M), proteinase K (0.5 mg/mL), and PBS pH 7.4 (3.5 mM) yielded the best results in the visual evaluations regarding the turbidity of the solution and reduction/dissolution of the fragment of skin (FIGURE 5), and in the detection of the *18S rRNA* gene by qPCR in terms of fluorescence amplitude and Ct. In the

porcine tissue used as a comparative model the mean Ct was 18.74 (range 17.45 to 19.40) in the detection of the 18S rRNA gene.

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

FIGURE 5. Demonstration of the simplified extraction protocol in clinical biopsy sample

After each 10-minute step, a reduction in skin fragments and a change in the turbidity of the solution were observed.

TABLE 5 – Results of Ct and average Cts obtained from evaluations for definition of the lysis solution for each simplified extraction protocol, derived from the detection of the mammalian 18S rRNA target by qPCR in porcine skin samples. Protocol numbers are summarized as 1 - Guanidine (2 M) and Urea (2 M); 2 -Urea (2 M); 3 - Guanidine (3 M) and Urea (4 M); 4 - Guanidine (4 M); 5 -Guanidine (5 M); 6 – NH₄OH (0.06 M); NC – Negative control.

Evaluated protocols – Molecular detection of the 18S rRNA target									
Protocols	1	2	3	4	5	6	NC		
	30.75	21.87	23.69	24.77	28.11	23.93	29.50		
Ct	26.57	21.16	23.11	23.03	28.81	31.68	29.78		
	29.08	22.08	24.26	23.62	27.76	25.01	29.27		
Mean Ct	28.80	21.70	23.69	23.81	28.23	26.87	29.52		

Evolution of elution protocols

Among the various elution protocols, the best outcomes, also assessed through amplification of the *18S rRNA* gene, were achieved using the 6 mm puncher, along with two washing steps employing 500 μ L of nuclease-free water, and subsequent incubation with 100 μ L of TE (pH 8.0) at 95 °C for 5 minutes in a thermal block. A schematic representation of the final comprehensive protocol is illustrated in FIGURE 6.

FIGURE 6. Schematic representation of the simplified DNA extraction protocol for *Mycobacterium leprae* from clinical skin biopsy samples. (Credit: Created in BioRender.com).

Analysis of clinical samples (skin biopsy) using a developed extraction protocol and portable platform (Q3-Plus)

The entire methodology developed, from DNA extraction using the simplified extraction protocol (SOLUTION 2 - TABLE 2) to qPCR analysis for the detection of *M. leprae* targets on the portable platform, was evaluated using clinical skin biopsy samples from patients with leprosy (MB and PB) and patients with other dermatoses (OD).

During visual assessment while extracting genetic material, a reduction in the skin biopsy fragment or its complete dissolution was observed, resulting in a visibly altered solution turbidity. Successful detection of the *18S rRNA* gene was also achieved. In reactions conducted on the standard equipment (QS-5), the mean Ct was 21.12 (ranging from 17.24 to 28.43), while on the Q3-Plus equipment, the mean Ct was 22.46 (ranging from 19.02 to 30.54).

In a Bland-Altman test conducted based on the same group of samples, with 95% confidence the *16S rRNA* target, presented the mean threshold cycle variation between paired samples was 1.29 cycles above on the Q3-Plus equipment (Supplemental Figure S4). For the detection of the *M. leprae* RLEP target, a mean variation of 4.44 threshold cycles above was observed for the Q3-Plus equipment (Supplemental Figure S5). Finally, for the 18S rRNA, a mean variation of 1.34 threshold cycles was observed (Supplemental Figure S6).

The qPCR reaction using the NAT Hans kit on the Q3-Plus equipment yielded positivity for *M. leprae* in 26% (14/53) of the samples, while 57% (30/53) of the samples tested negative for the agent, and 17% (9/53) of samples with indeterminate results.

For those analyses conducted on the standard equipment (QS-5), 30% (16/53) tested positive for the *M. leprae* agent, while 66% (35/53) yielded negative results. On this equipment, 4% (2/53) of the samples produced indeterminate results.

As for the sensitivity and specificity parameters of the testes, the portable platform (Q3-Plus) exhibited 52% and 87%, respectively. The reaction analyzed by the standard equipment (QS-5) showed 64% sensitivity and 93% specificity. Regarding the accuracy of the tests, it was 70 % for the Q3-Plus equipment and 80% for the QS-5 equipment. The positive predictive value (PPV) for the analyses conducted on the Q3-Plus equipment was 79%, whereas on the QS-5 equipment it was 88%. The negative predictive value (NPV) was 67% and 77% for the Q3-Plus and QS-5 equipment, respectively (TABLE 6).

TABLE 6 – Comparison of molecular diagnostic parameters in clinical biopsies extracted using both commercial and simplified protocols across different platforms

Parameters	Commercial extraction ABI7500	Simplified protocol Quantstudio-5	Simplified protocol Q3-Plus
Sensitivity	74%	64%	52%
Specificity	65%	93%	87%
Accuracy	69%	80%	70%
PPV	70%	88%	79%
NPV	69%	77%	67%

The standard analysis (commercial extraction method and standard thermocycler instrument) in the same group of the samples presented 38% (20/53) positives, 30% (16/53) negatives, and 32% (17/53) indeterminate results. Parameters of sensibility and specificity demonstrate 74% and 65%, respectively. Accuracy was estimated at 69%. Positive predictive value and negative predictive value were 70% and 69%, respectively.

Discussion

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

The utilization of screening tests in settings with restricted resources, along with their contribution to active case detection, holds paramount significance in achieving reduced leprosy incidence rates (BRASIL, 2022; STEINMANN et al., 2017). Considering the absence of a definitive gold standard test, the inherent constraints of adjunctive assays, and the clinical nuances of the disease, the advancement of assays characterized by high sensitivity and

specificity on portable platforms, accompanied by cost reduction and technique streamlining, facilitates the adoption of preventive and control interventions within the disease transmission continuum.

In the present study, the optimization of qPCR reactions on a portable analysis platform (Q3-Plus) was established using the oligonucleotides included in the first national diagnostic kit for leprosy, approved by ANVISA (kit NAT Hans – IBMP). Being a point-of-care device due to its compact dimensions, reaction volumes were optimized to 5 µL, requiring minor adjustments to oligonucleotide concentrations and master mix composition. Nevertheless, the Q3-Plus exhibited excellent efficiency values, closely approaching those of the standard equipment Quantstudio-5, highlighting the applicability of the platform in analytical contexts.

The efficiency of reaction is linked to the exponential amplification of the target material throughout the analysis. Factors such as the purity and concentration of the target in the sample and reagents, as well as the final volume of the qPCR reaction, are known determinants of the technique's efficiency (SVEC et al., 2015). Although the final reaction volume in the Q3-Plus equipment is five times smaller than that used in reactions analyzed in the standard equipment, the efficiency values remained close to 100%, which is desirable for this type of analysis (SVEC et al., 2015). Previous studies on reaction optimization for molecular detection of *Plasmodium* spp., *Trypanosoma cruzi*, and *Mycobacterium tuberculosis* had already noted higher efficiencies in the portable device when compared to the standard (ABI7500) (ALI et al., 2020; RAMPAZZO et al., 2019), as observed in the current study. This reinforces the possibility of this parameter being an anticipated trait of the Q3-Plus equipment.

The determination of the fluorescence threshold is an important tool to ensure that non-specific amplifications or other interferents do not generate false results in molecular qPCR tests. This parameter can be determined through numerical analysis or visually by the operator (CARAGUEL et al., 2011). Despite its subjectivity, in the present study, this parameter was manually defined by the operator through the observation of the fluorescence amplitude in known samples.

The reactions from synthetic DNA (gBlock®) in both instruments exhibited linearity up to 10¹ copies/µL, and beyond this range, amplifications started to occur stochastically. In the analyses of equivalent genome/µL of *M. leprae*, linearity in the instruments extended up to 10² equivalent genomes/µL; however, beyond this range, the Q3-Plus instrument lost analytical sensitivity for 16S rRNA target, while the QS-5 began to exhibit random amplifications. For the RLEP target, amplifications persisted beyond the linear range in both instruments. Given that this is a multicopy target, higher analytical sensitivity is expected (COLE et al., 2001). The loss of reaction linearity implies the occurrence of random amplifications, which could interfere particularly in cases classified as paucibacillary due to low bacillary load (MARTINEZ et al., 2014).

Through the analysis of the limit of detection (LOD_{95%}), it was possible to confirm greater sensitivity for the RLEP target. Reactions with purified *M. leprae* DNA yielded LOD values of 113.31 genome-equivalents/µL for the *16S rRNA* gene and 17.70 genome-equivalents/µL for RLEP on the Q3-Plus instrument. In a previous study by MANTA et al. (2020), the authors reported LOD values of 126 genome-equivalents/reaction for the *16S rRNA* and 1.3 genome-equivalents/reaction for the RLEP target, using the NAT Hans kit in a standard

thermocycler (ABI7500). This proximity of values ensures the good analytical sensitivity of the portable instrument. It is important to emphasize that the difference in $LOD_{95\%}$ values between the targets is expected, as RLEP is a repetitive element in the genome with approximately 36 copies (MANTA et al., 2022; COLE et al., 2001).

Analysis intra and inter-operator show very good results. All coefficients of variation were found to be below 5%. The three data points from intra-operator assessments that exceed this variation might be explained as they correspond to the lowest concentrations of the target DNA, falling outside or at the limit of the reaction, where the probability of amplification decreases and becomes stochastic.

In Bland-Altman analyses on pre-characterized clinical samples, a mean variation of approximately 1.40 cycles higher for the 16S rRNA target was observed on the Q3-Plus equipment compared to QS-5. For the RLEP target, the observed variation was approximately 5.15 cycles higher in the Q3-Plus evaluated samples. These values closely align with those reported by RAMPAZZO et al. (2019) from the optimization of the Q3 equipment for molecular detection of *T. cruzi* and *Plasmodium* spp. The disparity noted by these authors amounted to an increase of 2 to 4 Cts in Q3-Plus reactions.

The results obtained from optimization of reactions on the portable platform, concerning optical parameters, reaction efficiency, and analytical sensitivity, were confirmed in pre-characterized clinical samples extracted using the commercial kit (Qiagen). Analyses of sensitivity, specificity, and accuracy comparable to those of established qPCR tests on the standard equipment confirm the applicability of point-of-care testing. The occurrence of false

negatives is observed especially in paucibacillary cases (MARTINEZ et al., 2011; ROSA et al., 2013). The low bacterial load hinders the detection of these cases. However, qPCR is still considered the best technique to be used as a screening test complementary diagnostic due to its high sensitivity and specificity, particularly in detecting PB cases (MARTINEZ et al., 2011; WICHITWECHKARN et al., 1995).

Among the evaluated extraction protocols, certain chaotropic agents such as urea, guanidine, and ammonium hydroxide (NH₄OH) were considered. In this study the FTA cards aided in the isolation and purification steps of the genetic material. Due to their affinity for the cellulose fibers in the card, DNA recovery was feasible after the washing steps (DAIRAWAN & SHETTY, 2020).

FTA cards (Whatman®) are composed of cellulose fibers or other materials with affinity for genetic material (DNA). Their composition may include reagents capable of assisting in the cellular lysis and protein denaturation steps, such as sodium dodecyl sulfate (SDS) and sodium lauroyl sarcosinate (SLS), facilitating DNA exposure. They were developed to streamline sample transport and storage at room temperature, while ensuring DNA viability for molecular analyses of interest (BURGOYNE et al., 2003; AYE et al., 2011). They require minimal space for storage and have low risk of cross-contamination (SANTOS, 2018).

Regarding the application of urea solution (8 M) for DNA extraction from tissue samples, the results concerning the enhanced dissolution of skin fragments may be linked to the improved activity of proteinase K facilitated by high urea concentrations. Additionally, urea may have contributed to the preservation of the obtained genetic material, as reported in previous studies (AHMED, 1993; HILZ et al., 1975). Improved dissolution quality was also

observed through qPCR for the human *18S rRNA* target, as the Ct values were earlier than those found in extractions using other protocols and more consistent across replicates.

Regarding the analyses for *M. leprae* targets (16S rRNA and RLEP), there was a loss of sensitivity in the reactions from the simplified protocol-extracted samples, as evidenced by the increased Ct value in the 16S rRNA target when compared to the standard test performed by kit NAT Hans in samples extracted by commercial method (Qiagen).. Therefore, it is suggested that greater interference may be linked to the quality of genetic material extraction from the bacillus or residual extraction components that were not adequately removed during the purification/washing steps.

This decrease in sensitivity affects the detection of paucibacillary cases, as observed in the study samples. The reported sensitivity range varies (36.4% to 85%) in studies using qPCR for different targets and biological materials. In these studies, lower sensitivity is also observed for PB cases, demonstrating the intrinsic limitation in detecting this clinical form (BRAET et al., 2021; BARBIERI et al., 2019; MANTA et al., 2019; CHENG et al., 2019; AZEVEDO et al., 2017).

The results of the present study demonstrate the need for further protocol optimization to improve the detection of PB cases. However, the results presented are promising. The complete technological platform can serve as an auxiliary tool in detecting leprosy cases in remote regions and vulnerable populations. Social vulnerability, particularly observed in areas with low infrastructure, is relevant in perpetuating the disease transmission chain (de SOUZA et al., 2019; CABRAL-MIRANDA et al., 2014).

Furthermore, the possibility of using molecular tests may reduce recurring misdiagnoses in leprosy (NEVES et al., 2023; MANTA et al., 2020). Ensuring diagnosis for all populations is essential, and decentralizing access to it, as facilitated by active case finding, is pivotal for leprosy to discontinue being considered a public health problem in Brazil (BARBIERI et al., 2016). The Global Leprosy Strategy 2021-2030, published by the World Health Organization (WHO) (WHO, 2021), aims to eliminate the disease by interrupting transmission. However, there is a consensus that this goal will only be achieved with the improvement of the current strategies of complementary diagnosis, with an emphasis not only on developing strategies to increase the sensitivity of current tests, but also to increase access to available tests. The portable platform serves as a tool that, by adhering to the principles of the point-of-care testing concept, can contribute to overcoming some of the limitations in leprosy diagnosis.

As a limitation of this study, it should be considered that the samples were collected based on their occurrence in the clinic. The final clinical outcome of cases will be determined after one year of follow-up. Additionally, molecular test positivity can also occur in cases under treatment, where residual bacillus DNA may be present.

Conclusion

The optimization of qPCR reactions on the portable Q3-Plus platform for aiding leprosy diagnosis has shown promising potential for the full application of this technology as an auxiliary tool for healthcare professionals in suspected cases. Concerning the evaluated lysis solutions, the urea solution (2 M) demonstrated the best outcomes both visually, regarding fragment dissolution

and alteration of medium turbidity, and through qPCR assessment for the detection of the human 18S rRNA gene.

The complete technological solution (DNA extraction using a simplified protocol and qPCR analysis on the portable platform) yielded promising results. However, concerning the test's sensitivity, further optimization will be needed to enhance the detection of paucibacillary cases.

Acknowledgments

The authors are grateful to the entire team of dermatologists, nurses and technicians that collaborate at the Souza Araújo Clinic from the Leprosy Laboratory at the Oswaldo Cruz Institute. We especially thank Raquel Barbieri, Alexsandro Cruz Barreto and Cristiane Domingues for all the technical and administrative assistance.

This study was supported by grants from Carlos Chagas Filho Research Support Foundation of the State of Rio de Janeiro (E-26/203.913/2022) Carlos Chagas Institute Research Stimulus Program (ICC 008 FIO 21 – SUB 22) and by the National Fund for Health/Brazilian Ministry of Health (TED 69/2021). LSD is a CNPq fellowship holder, FSNM is a Faperj fellowship holder, and ADTC is a CNPq productivity fellow (level 2).

References

Ahmed FE. Urea facilitates quantitative estimation of DNA damage in Situ by preventing its degradation. Anal Biochem. 1993 May 1; 210(2): 253-257. doi: 10.1006/abio.1993.1192

- Ali N, Bello GL, Rossetti MLR, Krieger MA, Costa ADT. Demonstration of a fast 748
- 749 and easy sample-to-answer protocol for tuberculosis screening in point-of-care
- settings: A proof of concept study. PLoS ONE. 2020 Dec 14; 15 (12): e0242408. 750
- doi: 10.1371/journal.pone.0242408 751
- 752 Ali N, Rampazzo RDCP, Costa ADT, Krieger MA. Current Nucleic Acid Extraction
- Methods and Their Implications to Point-of-Care Diagnostics. BioMed Res Int. 753
- 754 2017 Jul 12; 2017. doi: 10.1155/2017/9306564
- Altman DG, Bland JM. Measurement in Medicine: The Analysis of Method 755
- Comparison Studies. Statistician. 1983; 32(3): 307-317. doi: 10.2307/2987937 756
- Aye KS, Matsuoka M, Kai M, Kyaw K, Aye A, Shwe MM, et al. FTA card utility for 757
- PCR detection of Mycobacterium leprae. Jpn J Infect Dis. 2011; 64(3): 246-248. 758
- doi: 10.7883/yoken.64.246 759
- Azevedo MDCS, Ramuno NM, Fachin LRV, Tassa M, Rosa PS, Belone AFF, 760
- Diório SM, Soares CT, Garlet GP, Trombone APF, gPCR detection of 761
- 762 Mycobacterium leprae in biopsies and slit skin smear of different leprosy clinical
- forms. Braz J Infect Dis. 2017 Feb; 21(1):71-78. doi: 10.1016/j.bjid.2016.09.017 763
- Barbieri RR, Manta FSN, Moreira SJM, Sales AM, Nery JAC, Nascimento LPR, 764
- et al. Quantitative polymerase chain reaction in paucibacillary leprosy diagnosis: 765
- 766 A follow-up study. PLoS Negl Trop Dis. 2019 Mar 5; 13(3): e0007147. doi:
- 10.1371/journal.pntd.0007147 767
- Barbieri RR, Sales AM, Hacker MA, Nery JAC, Duppre NC, Machado AM, et al. 768
- 769 Impact of a reference center on leprosy control under a decentralized public
- health care policy in Brazil. PLoS Negl Trop Dis. 2016 Oct 12;10(10): e0005059. 770
- 771 doi: 10.1371/journal.pntd.0005059

- Rosa FB, Souza VC, Almeida TAP, Nascimento VA, Vásquez FG, Cunha MGS, 772
- 773 et al. Detection of Mycobacterium leprae in saliva and the evaluation of oral
- sensitivity in patients with leprosy. Memorias do Instituto Oswaldo Cruz, 2013 774
- Aug; 108(5): 572-577. doi:10.1590/0074-0276108052013006 775
- Braet SM, Van Hooij A, Hasker E, Fransen E, Wirdane A, Baco A, et al. Minimally 776
- invasive sampling to identify leprosy patients with a high bacterial burden in the 777
- 778 Union of the Comoros. PLoS Negl Trop Dis. 2021 Nov 10; 15(11): e0009924. doi:
- 10.1371/journal.pntd.0009924 779
- 780 BRASIL. Protocolo Clínico e Diretrizes Terapêuticas da Hanseníase. Brasil,
- 2022. Publicado em: 20 jul. 2022. 781
- Burd EM. Validation of laboratory-developed molecular assays for infectious 782
- diseases. Clin Microbiol Rev. 2010 Jul 1; 23(3): 783 550-576. doi:
- 10.1128/crm.00074-09 784
- 785 Burgoyne LA, Smith M, Butt N. Dry solid medium for storage and analysis of
- 786 genetic material. US 6627226B2. Deposit: 2001 Mar 13. Concession: 2003 Sep.
- 30. 787
- Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The 788
- MIQE Guidelines: minimum information for publication of quantitative real-time 789
- 790 PCR experiments. Clin Chemistry. 2009 Apr 1; 55(4): 611-622. doi:
- 10.1373/clinchem.2008.112797 791
- Cabral-Miranda W, Chiaravalloti Neto F, Barrozo LV. Socio-economic and 792
- environmental effects influencing the development of leprosy in Bahia. 793
- north-eastern Brazil. Trop Med Int Health. 2014 Sep 22; 19(12):1504-1514. doi: 794
- 795 10.1111/tmi.12389

- Caraguel CGB, Stryhn H, Gagné N, Dohoo IR, Hammell KL. Selection of a cutoff 796
- 797 value for real-time polymerase chain reaction results to fit a diagnostic purpose:
- 798 Analytical and epidemiologic approaches. J Vet Diagn Invest. 2011 Jan 1;23(1):
- 2-15. doi: 10.1177/104063871102300102 799
- 800 Cheng X, Sun L, Zhao Q, Mi Z, Yu G, Wang Z, et al. Development and evaluation
- of a droplet digital PCR assay for the diagnosis of paucibacillary leprosy in skin 801
- 802 biopsy specimens. PLoS Negl Trop Dis. 2019 Mar 18; 13(3): e0007284. doi:
- 10.1371/journal.pntd.0007284 803
- Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. 804
- STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation 805
- and elaboration. BJM open. 2016; 6(11): e012799. doi: 10.1136/bmjopen-2016-806
- 012799 807
- Cole ST, Supply P, Honour N, Colston OJ. Repetitive sequences in 808
- 809 Mycobacterium leprae and their impact on genome plasticity. Lepr Rev. 2001
- Dec 1; 72(4):449-461. 810
- 811 Dairawan M, Shetty PJ, The evolution of DNA extraction methods. Am J Biomed
- 812 Sci Res. 2020 Mar 11; 8(1): 39-45. doi: 10.34297/AJBSR.2020.08.001234
- 813 de Souza CDF, Rocha VS, Santos NF, Leal TC, de Paiva JPS, Oliveira CCC, et
- 814 al. Spatial clustering, social vulnerability and risk of leprosy in an endemic area
- in Northeast Brazil: an ecological study. J Eur Acad Dermatol Venereol. 2019. 815
- doi: 10.1111/jdv.15596 816
- 817 Dharmawan Y, Fuady A, Korfage IJ, Richardus JH. Delayed detection of leprosy
- cases: A systematic review of healthcare-related factors. PLoS Negl Trop Dis. 818
- 819 2022 Sep; 16(9): e0010756. doi: 10.1371/journal.pntd.0010756

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

Dineva MA, Mahilum-Tapay L, Lee H. Sample preparation: a challenge in the development of point-of-care nucleic acid-based assays for resource-limited settings. Analyst. 2007 Oct 1; 132(12): 1193-1199. Han XY, Seo YH, Sizer KC, Schoberle T, May GS, Spencer JS, et al. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol. 2008 Jan 12; 130(6): 856-864. doi: 10.1309/AJCPP72FJZZRRVMM. Henry M, Galan N, Teasdale K, Prado R, Amar H, Rays M S, et al. Factors contributing to the delay in diagnosis and continued transmission of leprosy in Brazil – an explorative, quantitative, questionnaire based study, PLoS Negl Trop Dis. 2016 Mar 15; 10(3): e0004542. doi: 10.1371/journal.pntd.0004542 Hilz H, Wiegers U, Adamietz P. Stimulation of Proteinase K Action by Denaturing Agents: Application to the Isolation of Nucleic Acids and the Degradation of 'Masked' Proteins. Eur J Biochem. 1975 Aug; 56(1): 103-108. doi: 10.1111/j.1432-1033.1975.tb02211.x Hwang JH, Jeong H, Lee N, Hur S, Lee N, Han JJ, et al. Ex vivo live full-thickness porcine skin model as a versatile in vitro testing method for skin barrier research. Int J Mol Sci. 2021 Jan 11; 22(2): 657. doi: 10.3390/ijms22020657 Macieira S. Aspectos microbiológicos do Mycobacterium leprae. Noções de hansenologia. Bauru: Centro de estudos Dr Reynaldo Quagliato. Instituto Lauro de Souza Lima. 2000; 13-17. Madamet M, Amalvict R, Benoit N, Pradines B. Assessment of a Commercial Real-Time PCR Assay (Vitassay gPCR Malaria 5 Test) to Detect Human Malaria Infection in Travelers Returning to France. Diagnostics. 2022 Nov 10; 12(11): 2747. doi: 10.3390/diagnostics12112747

Manta FSN, Jacomasso T, Rampazzo RCP, Moreira SJM, Zahra NM, Cole ST, 844 845 et al. Development and validation of a multiplex real-time gPCR assay using GMP-grade reagents for leprosy diagnosis. PLoS Negl Trop Dis. 2022 Feb 18; 846 16(2): e0009850. doi: 10.1371/journal.pntd.0009850 847 Manta FSN, Leal-Calvo T, Moreira SJM, Margues BLC, Ribeiro-Alves M, Rosa 848 PS, et al. Ultra-sensitive detection of Mycobacterium leprae: DNA extraction and 849 850 PCR assays. PLoS Negl Trop Dis. 2020 May 26; 14(5): e0008325. doi: 10.1371/journal.pntd.0008325 851 Martinez AN, Ribeiro-Alves M, Sarno EN, Moraes MO. Evaluation of qPCR-852 Based assays for leprosy diagnosis directly in clinical specimens. PLoS Negl Trop 853 854 Dis, 2011 Oct 11;5(10): e1354. doi: 10.1371/journal.pntd.0001354 Martinez AN, Talhari C, Moraes MO, Talhari S. PCR-Based Techniques for 855 Leprosy Diagnosis: From the Laboratory to the Clinic. PLoS Negl Trop Dis. 2014 856 857 Apr 10;8(4): e2655. doi: 10.1371/journal.pntd.0002655 858 Neves KVRN, Machado LMG, Lisboa MN, Steinmann P, Ignotti E. Self-reported clinical history of misdiagnosed leprosy cases in the State of Mato Grosso, Brazil, 859 860 2016-2019. Cad. Saude Publica. 2023 Jul 17; 39: 6. doi: 10.1590/0102-861 311XEN279421 862 Rampazzo RCP, Graziani AC, Leite KK, Surdi JA, Biondo CA, Costa MLN, et al. Proof of Concept for a Portable Platform for Molecular Diagnosis of Tropical 863 Diseases: On-Chip Ready-to-Use Real-Time Quantitative PCR for Detection of 864 865 Trypanosoma cruzi or Plasmodium spp. J Mol Diag. 2019 Sep;21(5): 839-851. doi: 10.1016/j.jmoldx.2019.04.008 866

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

Rampazzo RCP, Zambenedetti MR, Alexandrino F, Jacomasso T, Tschá MK, de Fillipis AMB, et al. Development, verification, and validation of an RT-qPCRbased protocol for Yellow Fever diagnosis. Int J Infect Dis. 2022 Jun; 119: 34-37. doi: 10.1016/j.ijid.2021.12.361 Santos GC. FTA cards for preservation of nucleic acids for molecular assays a review on the use of cytologic/tissue samples. Archives of Pathology and Laboratory Medicine. Arch Pathol Lab Med. 2018 Mar 1; 142(3): 308-312. doi: 10.5858/arpa.2017-0303-RA Steinmann P, Reed SG, Mirza F, Hollingsworth TD, Richardus JH. Innovative tools and approaches to end the transmission of Mycobacterium leprae. Lancet Infect Dis. 2017 Sep; 17(9): e298-e305. doi: 10.1016/S1473-3099(17)30314-6 Summerfield A, Meurens F, Ricklin ME. The immunology of the porcine skin and its value as a model for human skin. Mol Immunol. 2015 Jul; 66(1): 14-21. doi: 10.1016/j.molimn.2014.10.023 Wang S, Lifson MA, Inci F, Liang L-G, Sheng Y-F, Demirci U. Advances in addressing technical challenges of point-of-care diagnostics in resource-limited settings. Expert Rev Mol Diagn. 2016 Feb 24; 16(4): 449-459. doi: 10.1586/14737159.2016.1142877 WHO. World Health Organization Leprosy. World Health Organization. 2022. WHO. World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. OMS. 2018.

891

892

895

897

899

901

904

905

907

909

WHO. World Health Organization. Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm. Copenhagen: 889 890 WHO Regional Office for Europe. 2020 Feb 6. WHO. World Health Organization. Towards zero leprosy. Global leprosy (Hansen's Disease) strategy 2021-2030. 2021. Wichitwechkarn J, Karnjan S, Shuntawuttisettee S, Sornprasit C, Kampirapap K, 893 Peerapakorn S. Detection of *Mycobacterium leprae* infection by PCR. J Clin 894 Microbiol. 1995 Jan 1;33(1):45-49. doi: 10.1128/jcm.331.45-49.1995 896 Yu CY, Chan KG, Yean CY, Ang GY. Nucleic acid-based diagnostic tests for the detection SARS-CoV-2: An update. Diagnostics. 2021; 11(1): 53. doi: 10.3390/diagnostics11010053 898 **List of Supplementary Material** 900 Supplemental Table S1. Information regarding clinical samples, gender, age and clinical diagnosis collected at the Hansen's disease Laboratory of Oswaldo 902 903 Cruz Institute – Fiocruz – RJ. Key: PB – Paucibacillary; MB – Multibacillary; OD Other dermatoses. Supplemental Table S2. MIQE checklist. 906 Supplemental Table S3. STARD checklist. Supplemental Figure S1. Bland-Altman analysis for the 16S rRNA target 908 detected in the portable instrument versus the benchtop instrument. The mean

difference it was 1.40 cycle of threshold between instruments. The upper limit of

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

agreement with 95% confidence interval was 9.40 and the lower limit of agreement was -6.61. Supplemental Figure S2. Bland-Altman RLEP (Optimization multiplex gPCR) Q3-Plus). Bland-Altman analysis in RLEP target. The mean difference it was 5.15 cycle of threshold between the equipment in 95% confidence interval. The upper limit of agreement was 10.59 and the lower limit of agreement was -0.28. Supplemental Figure S3. Bland-Altman 18S rRNA (Optimization multiplex qPCR Q3-Plus). Bland-Altman analysis in 18S rRNA target. The mean difference it was 1.42 cycle of threshold between the equipment in 95% confidence interval. The upper limit of agreement was 3.25 and the lower limit of agreement was -0.40. Supplemental Figure S4. Bland-Altman 16S rRNA (Evaluated simplified extraction protocol in clinical samples analyzed in Q3-Plus). Bland-Altman analysis in 16S rRNA target. The mean difference it was 1.29 cycle of threshold between the equipment in 95% confidence interval. The upper limit of agreement was 12.39 and the lower limit of agreement was -9.81. **Supplemental Figure S5.** Bland-Altman RLEP (Evaluated simplified extraction protocol in clinical samples analyzed in Q3-Plus). Bland-Altman analysis in RLEP target. The mean difference it was 4.44 cycle of threshold between the equipment in 95% confidence interval. The upper limit of agreement was 11.91 and the lower limit of agreement was -3.04. Supplemental Figure S6. Bland-Altman 18S rRNA (Evaluated simplified extraction protocol in clinical samples analyzed in Q3-Plus). Bland-Altman

analysis in 18S rRNA target. The mean difference it was 1.34 cycle of threshold

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963


MOM

between the equipment in 95% confidence interval. The upper limit of agreement was 6.90 and the lower limit of agreement was -4.22. **Author contribution list** Specific Contributions: 1. ABS (Lead Author) a. Collected and analyzed the data; b. Drafted the initial manuscript. 2. LSD a. Laboratory support 3. MRA a. Responsible for statistical analyses b. Revised the manuscript; 4. RPO a. Revised the manuscript; b. Provided funding 5. FSNM a. Design of the study; b. Supervised sample collection; c. Performed, and analyzed same experiments: d. Contributed to the interpretation of results; e. Revised the manuscript; 6. ADTC a. Design of the study; b. Conceptualized the study c. Contributed to the interpretation of results; d. Supervised lab data collection e. Provided funding f. Critically reviewed intellectual content.


a. Provided funding; 964

966


b. Conceptualized the study 965




Figure_1




Figure_2




Figure_4



Figure_3





Figure_5

